Caley Castelein
CIK 1355758 · last filed 2026-06-15
Caley Castelein is a corporate insider who has filed 46 SEC Form 4 insider transactions across 5 companies since 2016. The most recent filing, for WHWK, was dated Jun 15, 2026. Across all open-market trades the lifetime net is +$7.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $7.6M across reported positions. 2 SEC filings were submitted jointly with Anupam Dalal. 3 Form 144 notices of planned sales are also on file; the latest, for ViewRay, Inc. on Jul 19, 2023, lists the filer as a director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRAY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE MONTGOMERY STREET
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WHWK | Director | 2,440,794 | $3.13 | $7.64M | $0 | 3 | 2026-06-15 |
| Tourmaline Bio, Inc. (TRML) Delisted | Director | 0 | $47.98 | $0 | $280.6K | 5 | 2025-10-28 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | 2,185,692 | $2.05 | $4.48M | $3.40M | 6 | 2025-03-04 |
| ViewRay, Inc. (VRAY) Delisted | Director | 99,047 | $0.03 | $2.5K | $3.44M | 20 | 2023-07-21 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Director | 19,694 | $33.00 | $649.9K | $0 | 6 | 2021-07-02 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| WHWK | Direct | 274,796 | 11.3% | 2026-05-18 |
| KVP Capital, LP See footnote |
2,165,998 | 88.7% | 2026-05-18 | |
| Total | 2,440,794 | |||
| TRML | Direct | 0 | — | 2025-10-28 |
| By KVP Capital, LP | 0 | — | 2025-10-28 | |
| Total | 0 | |||
| AADI | Direct | 19,694 | 0.9% | 2025-03-04 |
| KVP Capital, LP See footnote |
2,165,998 | 99.1% | 2025-03-04 | |
| Total | 2,185,692 | |||
| VRAY | Direct | 99,047 | 100.0% | 2023-07-21 |
| KVP Capital, L.P. See footnote |
0 | 0.0% | 2023-07-21 | |
| Total | 99,047 | |||
| ARPO | Direct | 19,694 | 100.0% | 2021-07-02 |
| See Footnote | 0 | 0.0% | 2018-09-26 | |
| Total | 19,694 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | WHWK | Grant (A) | +255,102 | $1000.0K | EDGAR |
| 2025-10-28 | Tourmaline Bio, Inc. (TRML) Delisted | Mixed | −947,936 | $0 | EDGAR |
| 2025-10-17 | Tourmaline Bio, Inc. (TRML) Delisted | Gift (G) | −522 | $0 | EDGAR |
| 2025-06-16 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | +1,666,000 | $4.00M | EDGAR |
| 2024-06-14 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-10-27 | Tourmaline Bio, Inc. (TRML) Delisted | Buy (P) | +20,000 | $280.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).